Teleflex Global Regulatory Dossier: Arrow, UroLift, FDA Data & 2025 Sale

Data-driven regulatory dossier of Teleflex (NYSE: TFX): ~440 FDA 510(k)s, multi-country registration counts, Arrow Class I recalls, and the 2025 $2.03B divestiture.

Executive Summary & Key Findings

Teleflex Incorporated (NYSE: TFX) is a global provider of medical technologies designed to enhance clinical benefits and improve patient and provider safety. The company's portfolio is anchored by major commercial brands including Arrow (vascular access and critical care), UroLift (interventional urology for benign prostatic hyperplasia), LMA and Rüsch (airway management and anesthesia), and Teleflex Medical OEM (custom extrusion, suture, and catheter compounding).

Based on an analysis of public regulatory filings, global registry snapshots, and financial disclosures through mid-2026, Teleflex presents a distinct regulatory and postmarket profile:

FY2024 Net Revenue: Teleflex generated $3,047.3 million in net revenue (+2.4% YoY growth), supported by three primary reportable segments: Americas ($1,850M+ annual revenue), EMEA ($650M+ annual revenue), and Asia-Pacific.
FDA Premarket Portfolio: Counted across its corporate entities (Arrow/Teleflex, Vascular Solutions, and NeoTract), Teleflex holds roughly 440 active 510(k) clearances — about 300 under the Arrow and Teleflex names, plus about 123 under Vascular Solutions and 17 under NeoTract (UroLift). Its Class III PMA footprint is narrow: 2 distinct PMA devices (the MANTA vascular closure device, P180025, and the legacy Vascular Solutions Duett/D-Stat hemostatic sealing device, P990037), represented by 47 PMA record rows (mostly supplements). Arrow's vascular-access and balloon-catheter lines are 510(k)-cleared Class II devices, not PMAs.
FDA Establishment & Listing Footprint: The company maintains 2,386 active establishment registration and device listing record rows in FDA databases across manufacturing plants in the US, Mexico, Malaysia, and Ireland.
Postmarket Safety Exposure: Teleflex shows a high-frequency Class I recall history concentrated in its Arrow vascular access and intra-aortic balloon catheter lines, including major recall notices for radial artery lines, central venous catheters, and intra-aortic balloon pumps.
Multi-Country Registration Depth: Teleflex holds an extensive international registration footprint led by Health Canada (632 active MDALL licenses), India CDSCO (327 approved licenses), South Korea MFDS (292 device registrations), Saudi Arabia SFDA (272 authorizations), Australia TGA ARTG (267 active listings), and Singapore HSA (138 registered devices).
2025 Portfolio Refocus (Sale, Not Spinoff): After first announcing (February 2025) a plan to spin off its Urology, Acute Care, and OEM businesses into a new public company, Teleflex instead disclosed on December 9, 2025 definitive agreements to sell those businesses for a combined $2.03 billion to two buyers — Intersurgical (Acute Care and Interventional Urology) and the private-equity firms Montagu and Kohlberg (OEM) — leaving a focused "RemainCo" built around vascular access, interventional, and surgical franchises. The sales are expected to close in the second half of 2026.

Direct Answer: Teleflex Market-Access & Regulatory Footprint Overview

In 2024, Teleflex generated $3,047.3 million in net revenues across three geographic reportable segments: Americas ($540.8 million in Q4 2024), EMEA ($161.0 million in Q4 2024), and Asia-Pacific. On the FDA regulatory side, Teleflex's corporate entities hold roughly 440 active 510(k) clearances (about 300 under the Arrow/Teleflex names, ~123 under Vascular Solutions, and ~17 under NeoTract/UroLift) plus a narrow Class III footprint of 2 distinct PMA devices — the MANTA vascular closure device (P180025) and the legacy Vascular Solutions Duett/D-Stat hemostatic device (P990037). Outside the United States, Teleflex maintains an extensive regulatory footprint across Health Canada (632 active MDALL licenses), Korea MFDS (292 approvals), India CDSCO (327 registrations), Saudi SFDA (272 authorizations), Australia ARTG (267 listings), and Singapore HSA (138 registrations).

Teleflex's corporate structure is mid-transition. After announcing a spinoff plan in February 2025, the company pivoted and on December 9, 2025 agreed to sell its Acute Care, Interventional Urology (UroLift), and OEM businesses for a combined $2.03 billion — Acute Care and Interventional Urology to Intersurgical, and OEM to Montagu and Kohlberg. The remaining company ("RemainCo") keeps the Arrow vascular-access, interventional, and surgical franchises. The transactions are expected to close in the second half of 2026.

Teleflex at a Glance: Segments, Revenue, and Brand Portfolio

Teleflex was founded in 1943 as a mechanical control cable manufacturer for WWII aircraft. Over the past three decades, the company transformed through targeted medtech acquisitions into a specialized clinical device provider. Today, Teleflex operates as a premier provider of critical care, diagnostic, and interventional devices, with a commercial presence spanning over 150 countries.

Geographic Segment Performance and Commercial Structure

Teleflex organizes its commercial operations into three primary reportable geographic segments:

Americas Segment: Represents the largest commercial market for Teleflex, generating over $1.85 billion annually (including $540.8 million in Q4 2024). The Americas market is characterized by high penetration of Arrow acute central venous catheters, pressure-injectable peripherally inserted central catheters (PICCs), and the UroLift System across US hospital networks and ambulatory surgical centers (ASCs).
EMEA Segment (Europe, Middle East, Africa): Generates approximately $650 million annually ($161.0 million in Q4 2024). Commercial distribution in Europe is supported by direct sales forces in major Western European countries (Germany, France, UK, Italy, Spain) and authorized distributor networks in Eastern Europe and the Middle East. The European business is heavily weighted toward critical care, anesthesia airway management (LMA and Rüsch), and OEM manufacturing.
Asia-Pacific Segment: Represents Teleflex's fastest-growing geographic region, with key commercial markets in China, Japan, India, South Korea, and Australia. Growth in Asia-Pacific is driven by expanding critical care hospital infrastructure, increased demand for infection-resistant central lines, and rising adoption of interventional cardiac products.

Core Brand Franchises and M&A History

Teleflex's product portfolio is built upon several transformative acquisitions that established its clinical market leadership:

Arrow International: Acquired in October 2007 for approximately $2.0 billion ($45.50 per share). Arrow is the world leader in central venous catheterization and arterial catheterization, representing the single largest revenue and regulatory anchor for Teleflex. The Arrow portfolio includes central venous access kits, hemodialysis catheters, arterial lines, intra-aortic balloon pumps, and specialized catheter coatings.
NeoTract (UroLift System): Acquired in October 2017 for $725 million upfront plus up to $375 million in milestone payments. NeoTract developed the UroLift System, a minimally invasive transprostatic tissue retraction device designed to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH) without cutting or heating prostate tissue.
Vascular Solutions: Acquired in February 2017 for $1.0 billion. This acquisition added specialized interventional cardiology and peripheral vascular access products to Teleflex's portfolio, including guide extension catheters (GuideLiner), hemostatic patches, and microcatheters.
Pyng Medical (EZ-IO Intraosseous System): Acquired to expand Teleflex's emergency medicine portfolio. The EZ-IO system provides rapid intraosseous vascular access for adult and pediatric patients when intravenous access is difficult or impossible during emergency resuscitation.
Biotronik Vascular Intervention: In February 2025, Teleflex agreed to acquire Biotronik's Vascular Intervention business for approximately €760 million (~$830 million), and Teleflex announced completion of the acquisition on July 1, 2025. The deal expanded its peripheral vascular balloon angioplasty, nitinol stent, and drug-eluting balloon portfolio across European and global markets.

In-Depth Analysis of Key Product Lines and Clinical Evidence

1. Arrow Vascular Access & Antimicrobial Protection Technology

Arrow International established its clinical leadership through the development of specialized catheter coatings designed to reduce catheter-related bloodstream infections (CRBSIs), which represent a major cause of hospital-acquired morbidity and mortality in intensive care units (ICUs).

The Arrowg+ard Blue technology utilizes molecular impregnation of chlorhexidine acetate and silver sulfadiazine on the exterior surface of central venous catheters. Clinical trials have demonstrated that Arrowg+ard Blue coating reduces CRBSI incidence by up to 79% compared to uncoated lines. To extend protection to internal catheter lumens during prolonged ICU dwell times, Teleflex developed Arrowg+ard Blue Plus technology, which impregnates both interior lumens and exterior surfaces, providing antimicrobial elution lasting up to 30 days.

In addition to antimicrobial protection, Arrow manufactures high-flow polyurethane catheters engineered to withstand power-injector pressures up to 300 psi and flow rates up to 5 mL/sec. These pressure-injectable PICCs and midlines allow clinicians to perform contrast-enhanced computed tomography (CT) imaging without inserting a separate peripheral IV line, significantly streamlining emergency and inpatient radiology workflows.

2. NeoTract UroLift System: Clinical Evidence and Coding

The UroLift System utilizes permanent transprostatic implants to lift and hold enlarged prostate lobes out of the way, widening the urethral lumen without heating, cutting, or destroying prostate tissue. The delivery device is inserted transurethrally under cystoscopic visualization to place nitinol and stainless steel implants anchored by a PET suture thread.

Clinical evidence supporting the UroLift System is anchored by the prospective, randomized, double-blind, sham-controlled pivotal LIFT study. Long-term 5-year follow-up data published from the LIFT study demonstrated rapid symptom relief (International Prostate Symptom Score improvement exceeding 8 points), sustained peak urinary flow rate improvements (Qmax), zero de novo, permanent erectile or ejaculatory dysfunction, and a low 5-year surgical retreatment rate of 13.6%.

From a market access perspective, the UroLift procedure bills under dedicated Category 1 CPT codes: CPT 52441 (cystourethroscopy with insertion of transprostatic implant; first implant) and CPT 52442 (each additional implant). Securing dedicated CPT coding and universal commercial coverage across Medicare, Aetna, Cigna, Humana, and UnitedHealthcare was instrumental in driving commercial adoption following Teleflex's acquisition of NeoTract.

3. Teleflex MANTA Large-Bore Closure Device: PMA P180025

Approved by the FDA under Premarket Approval P180025 in February 2019, MANTA is a dedicated vascular closure device specifically engineered for large-bore femoral arterial access following structural heart and endovascular procedures.

Prior to MANTA, interventional cardiologists performing transcatheter aortic valve replacement (TAVR) or endovascular abdominal aortic aneurysm repair (EVAR) relied on suture-based pre-close techniques (such as Abbott Perclose ProGlide). Suture pre-close techniques require placing sutures into the femoral artery prior to inserting large-bore sheaths (12F to 25F outer diameter) and tying manual knots after procedure completion, which carries risks of suture tear, vessel stenosis, and persistent bleeding.

MANTA introduced a collagen-based closure mechanism that does not require pre-close suture deployment. The device deploys an intra-arterial resorbable poly-caprolactone (PCL) toggle inside the vessel and an extra-arterial bovine collagen pad outside the vessel wall, sandwiching the arteriotomy to achieve rapid mechanical hemostasis. The pivotal SAFE-MANTA clinical trial demonstrated a 94.7% procedural success rate, a median time-to-hemostasis of 2.4 minutes, and low rates of major access-site vascular complications in TAVR and EVAR patients.

4. Biotronik Vascular Intervention Acquisition (€760M / ~$830M)

The February 2025 agreement to acquire Biotronik's Vascular Intervention business significantly strengthens Teleflex's peripheral interventional presence outside the US. Key assets acquired in the transaction include:

Passeo-18 and Passeo-35 PTA Balloons: High-pressure percutaneous transluminal angioplasty (PTA) balloon catheters designed for dilating stenotic lesions in infrapopliteal and femoral-popliteal arteries.
Pulsar-18 Nitinol Stent: A self-expanding, thin-strut nitinol stent system optimized for treating peripheral artery disease (PAD) in the superficial femoral artery (SFA), featuring micro-struts that reduce vessel wall stress and restenosis.
Pantera Lux DEB: A drug-eluting balloon catheter coated with paclitaxel, designed to inhibit neointimal hyperplasia in coronary and peripheral in-stent restenosis procedures.

FDA Footprint: 510(k), PMA, Registration, and Product Code Analysis

An analysis of FDA premarket submissions shows that Teleflex operates primarily in Class II (510(k) cleared) and Class III (PMA approved) interventional categories.

FDA Premarket Approval and Clearance Tally

Counted across all of Teleflex's corporate entity names, the family holds roughly 440 active 510(k) clearances — about 300 under the Arrow International and Teleflex names, roughly 123 under Vascular Solutions, and about 17 under NeoTract (the UroLift subsidiary). It also maintains 2,386 active establishment registration and device listing record rows, reflecting its network of manufacturing plants, packaging sites, and distribution hubs.

510(k) Clearance Distribution by Product Code

The Arrow/Teleflex-named 510(k) clearances (about 300) are dominated by vascular access and surgical/airway devices. The leading FDA product codes, each with a representative cleared device, are:

GAT — nonabsorbable surgical suture (OEM): 13 clearances, e.g. Force Fiber black co-braid polyethylene suture (Teleflex Medical OEM).
LJS — percutaneous intravascular catheter (vascular access): 10 clearances, e.g. the CG+ Arrow PICC powered by the Arrow VPS stylet.
DYB — introducer sheath/dilator (vascular access): 9 clearances, e.g. the Arrow GlideThru peel-away sheath/dilator introducer.
FZP — ligating clip/applier (surgical): 9 clearances, e.g. the Weck Auto Endo5 automatic endoscopic applier.
BTR — airway device (anesthesia/respiratory): 8 clearances, e.g. Sheridan Spiral-Flex endotracheal tubes.
FOZ — intravascular catheter (vascular access): 7 clearances, e.g. the Arrow Endurance extended-dwell peripheral catheter system.
BTT — respiratory accessory: 7 clearances, e.g. Hudson RCI Aquapak humidifier adaptors.
GCJ — laparoscopic access port (surgical): 6 clearances, e.g. the Weck Vista optical bladeless access port.
DQX — guidewire (interventional): 5 clearances, e.g. the Teleflex Teflon-coated guidewire.
EZL — urological catheter: 5 clearances, e.g. Rusch Simplastic Foley catheters.
CAZ — regional/anesthesia catheter: 5 clearances, e.g. the Arrow epidural catheter kit.

This mix is itself a preview of the 2025 divestiture: the BTR, BTT, and EZL airway, respiratory, and Foley lines fall within the Acute Care and urology businesses Teleflex agreed to sell, while the Arrow vascular-access (LJS, DYB, FOZ, DQX, CAZ) and Weck surgical (FZP, GCJ) lines stay with RemainCo.

Premarket Approval (PMA) Portfolio

Teleflex's Class III PMA footprint is narrow — 2 distinct PMA devices, not a broad high-risk portfolio:

Teleflex MANTA Vascular Closure Device (P180025): approved in February 2019 for large-bore femoral arterial access closure after structural-heart and endovascular procedures. The 15 Teleflex PMA record rows are almost entirely MANTA supplements.
Vascular Solutions Duett / D-Stat hemostatic sealing device (P990037): a legacy PMA (with 32 record rows, mostly supplements) covering the Duett sealing device and D-Stat flowable hemostat.
Arrow's intra-aortic balloon (IAB) catheters and broad vascular-access lines are 510(k)-cleared Class II devices, not PMA products — an important distinction for anyone modeling Teleflex's Class III risk exposure.

For methodology comparison with other major medtech regulatory dossiers, see our analysis of the Boston Scientific FDA device footprint and Medtronic FDA device footprint.

Global Manufacturing & Registered Operations Footprint

Teleflex operates a network of major manufacturing, assembly, and sterilization facilities registered with the FDA and international notified bodies across North America, Europe, and Asia.

Key Manufacturing Hubs and Technical Capabilities:

Based on FDA establishment registration and device listing records filed under the Teleflex entity names, the company's principal registered sites span the US, Mexico, Malaysia, and Ireland:

Morrisville, North Carolina (Research Triangle Park area): The largest US listing footprint by record count and a primary R&D and manufacturing base for Arrow vascular-access catheters and hemodynamic monitoring systems.
Olive Branch, Mississippi: A high-volume US manufacturing and assembly site supporting Arrow critical-care and vascular-access product lines.
Wyomissing, Pennsylvania: Long-time corporate manufacturing and operations center for Teleflex and Arrow.
Tecate and Nuevo Laredo, Mexico: Major high-volume sites for surgical instruments and ligating clips, producing Weck Hem-o-lok clips, laparoscopic instruments, and catheter sub-assemblies.
Kamunting, Malaysia: Specialized rubber, latex, and silicone processing facility manufacturing Rüsch endotracheal tubes, Foley catheters, and urinary drainage systems.
Limerick and Athlone, Ireland: Advanced extrusion and manufacturing hub, including MANTA closure-device production and complex interventional catheter shafts.
Plymouth, Minnesota: Dedicated manufacturing site for NeoTract UroLift delivery devices and nitinol implant sub-assemblies.

Teleflex Medical OEM Capabilities

Teleflex Medical OEM operates as a specialized business unit providing custom contract manufacturing services to other medical device companies worldwide. Its technical capabilities include:

Custom Suture & Braiding: Manufacturer of Force Fiber ultra-high molecular weight polyethylene (UHMWPE) high-strength sutures, bioabsorbable PGA/PLLA sutures, and custom co-braided constructs for orthopedic sports medicine and surgical closure.
Precision Micro-Extrusion: Single-lumen, multi-lumen, co-extruded, and profile tubing using fluoropolymers (PTFE, FEP, ETFE) and thermoplastics (PEBAX, polyurethane, nylon) with wall thicknesses down to 0.005 inches.
Catheter Compounding: Custom polymer blending with radiopaque fillers (barium sulfate, bismuth subcarbonate), custom color matching, and antimicrobial additive masterbatch compounding.

To analyze how manufacturing sites support global listings, consult our guide on global manufacturing footprint and FDA establishment registration.

Multi-Country Regulatory Footprint: Global Registration Comparison

Outside the US, Teleflex maintains active medical device registrations across all major global regulatory jurisdictions. The analysis below compiles computed registration counts across official national health authority registries as of mid-2026 database exports:

Canada (Health Canada MDALL): 632 active device licenses. Health Canada represents Teleflex's largest single international registry footprint, reflecting deep market penetration of Arrow central venous catheters, PICCs, and Rüsch airway systems across Canadian provincial hospital networks.
India (CDSCO): 327 approved device licenses. Reflects rapid commercial expansion of Arrow critical care lines and anesthesia products across Indian private healthcare chains.
South Korea (MFDS): 292 device registrations. Korean Ministry of Food and Drug Safety approvals cover Arrow vascular access kits, LMA laryngeal masks, and UroLift systems.
Saudi Arabia (SFDA): 272 medical device authorizations. Strong Middle Eastern footprint supporting hospital critical care infrastructure projects in Saudi Arabia and the Gulf Cooperation Council (GCC).
Australia (TGA ARTG): 267 active listings. Australian Register of Therapeutic Goods entries cover the full spectrum of Teleflex critical care, vascular, and urology devices.
Singapore (HSA): 138 registered medical devices. Serves as Teleflex's Southeast Asian regulatory and commercial hub.
European Union (EUDAMED): 26 registered economic actor profiles (across the US, Ireland, Germany, Malaysia, Italy, and Spain) and 19 device family records actively transitioning under EU MDR (Regulation 2017/745).
United Kingdom (MHRA): 6 registered manufacturer entities managing post-Brexit UKCA and CE mark transitional listings.
Brazil (ANVISA): 0 direct "Teleflex LLC" registrant rows in public query databases. In Brazil, Teleflex commercializes products through local registration holders (Detentor do Registro) and specialized commercial distribution partners, rather than holding direct corporate registrations.

Postmarket Safety: Arrow Class I Recalls and Enforcement Record

While Teleflex holds a leading market share in vascular access, its heavy focus on invasive central lines, arterial catheters, and intra-aortic balloon pumps exposes the company to significant postmarket regulatory scrutiny. In FDA postmarket databases, the Teleflex and Arrow International entity names together account for roughly 1,190 recall line-item records and 408 enforcement report entries (recall and enforcement rows are individual product records, not unique recall events — a single recall can generate many rows).

Case Study 1: Arrow QuickFlash Radial Artery Catheterization Kits (April 2024)

In April 2024, the FDA classified a Class I recall for 334,995 Arrow QuickFlash Radial Artery and Radial Artery/Arterial Line Catheterization Kits (distributed December 2021 through January 2024).

Failure Mechanism: Reports of increased resistance in the guidewire handle and chamber during use, which can cause arterial vasospasm, vessel-wall injury, or embolism from repeated puncture attempts.
Adverse Clinical Impact: Teleflex/Arrow received 194 complaints, with 10 injuries and 1 death reported.
Regulatory Action: Teleflex sent an Urgent Medical Device Recall letter on February 12, 2024 instructing customers to identify and quarantine affected kits.

Case Study 2: Arrow Catheter Separation/Leakage Recall (June 2023)

In June 2023, Teleflex/Arrow recalled more than 250,000 catheters — including Arrow Endurance extended-dwell peripheral catheter systems and related lines — after reports of catheter separation or leakage. If a catheter separates during venous or arterial use, fragments can migrate and cause vessel blockage, ischemia, clotting, pulmonary embolism, heart attack, or death. Teleflex received 83 complaints and 18 patient injuries between May 2018 and May 2023; no deaths were reported.

Case Study 3: Arrow FiberOptix and UltraFlex IAB Catheter Kits (June 2024)

In June 2024, the FDA classified a Class I recall for Arrow FiberOptix and UltraFlex Intra-Aortic Balloon (IAB) Catheter Kits (16,959 devices distributed May 2022 through April 2024; recall initiated April 29, 2024). A manufacturing error can cause the balloon to become overtwisted, preventing full inflation, allowing helium to leak, and causing blood backup or catheter damage — risks that can lead to blood loss, artery perforation, hemodynamic instability, or death. This was the more severe of the two 2024 Arrow recalls, with 31 injuries and 3 deaths reported across 322 complaints.

Case Study 4: Arrow Pressure Injectable Catheter Kits Mislabeling (November 2023)

In November 2023, the FDA classified a Class I recall for 1,905 Arrow Pressure Injectable Catheter Kits because some kits coated with chlorhexidine were mislabeled. The concern is patient harm — including anaphylaxis — if a chlorhexidine-allergic patient inadvertently uses a mislabeled kit. There were 16 reported incidents and no injuries or deaths.

For broader comparative recall analysis across device categories, see our guide on FDA recall and clearance analysis.

The 2025 Portfolio Refocus: From Planned Spinoff to a $2.03 Billion Sale

Teleflex's corporate structure changed course during 2025, and the final outcome is a sale rather than the spinoff that was first announced. This matters for anyone modeling how Teleflex's regulatory ownership and registered footprint will be reallocated.

February 2025: The Original Spinoff Plan

On February 27, 2025, Teleflex announced its intent to separate into two independent, publicly traded companies via a tax-free distribution of newly issued shares. The plan was to spin off Urology, Acute Care, and OEM into a new public company ("NewCo"), while a "RemainCo" kept the vascular-access, interventional, and surgical franchises.

December 2025: The Pivot to a Sale

On December 9, 2025, Teleflex announced it had instead signed definitive agreements to sell those same businesses for a combined $2.03 billion in cash to two sets of buyers:

Acute Care and Interventional Urology → Intersurgical Ltd. (UK), for approximately $530 million. This transfers the anesthesia, respiratory, and airway franchises (the LMA and Rüsch brands) plus the UroLift interventional-urology business.
OEM → the private-equity firms Montagu and Kohlberg, for approximately $1.5 billion. This transfers Teleflex Medical OEM (custom suture, extrusion, and catheter compounding).

Teleflex expected net proceeds of roughly $1.8 billion after tax, primarily earmarked for share repurchases (the board authorized a new $1 billion buyback) and debt paydown. The transactions are expected to close in the second half of 2026, subject to regulatory approvals.

What Stays With Teleflex ("RemainCo")

The remaining company keeps the Vascular Access, Interventional, and Surgical franchises — anchored by Arrow central venous and arterial access, Vascular Solutions and the acquired Biotronik Vascular Intervention lines, the Weck surgical closure portfolio, and the MANTA vascular closure device. Liam Kelly continues as Chair, President, and CEO. On a pro-forma basis (including Biotronik VI), RemainCo represented about $2.1 billion of 2024 revenue versus roughly $1.4 billion for the divested businesses.

Regulatory and Market-Access Implications

Isolating Vascular Postmarket Exposure: Whether executed as a spinoff or a sale, the transaction separates the higher-growth urology and OEM assets from the Class I recall and critical-care exposure concentrated in the Arrow vascular-access lines that stay with Teleflex.
License and Registration Transfers: Before closing, Teleflex regulatory teams must execute global transfer applications across FDA, Health Canada, TGA, EU notified bodies, and other regulators to reassign 510(k) ownership, CE mark certificates, and country registrations for the divested Acute Care, Urology, and OEM product lines to Intersurgical and the OEM buyers. The multi-country registration counts above (for example the anesthesia and airway registrations under MDALL, MFDS, and ARTG) will need to be split between RemainCo and the acquiring companies.

Regulatory & Market-Access Benchmark Summary

For medtech competitors, hospital procurement teams, and regulatory strategists, Teleflex's global footprint provides key lessons in portfolio management:

Managing Single-Brand Regulatory Risk: Over-reliance on a single flagship brand (Arrow) for a large percentage of corporate revenue creates concentrated Class I recall exposure. Medical device manufacturers must implement rigorous corrective and preventive action (CAPA) systems to mitigate postmarket risk.
A Narrow Class III Footprint: Teleflex's Class III PMA portfolio is intentionally narrow — essentially the MANTA vascular closure device (P180025) and the legacy Vascular Solutions Duett/D-Stat hemostat (P990037). Its flagship Arrow vascular-access and intra-aortic balloon catheter lines are 510(k)-cleared Class II devices, so most of the postmarket recall risk sits in the 510(k), not the PMA, tier.
Global Registry Buffering: Maintaining broad registration depth across tier-2 international markets (Canada, India, South Korea, Saudi Arabia) buffers top-line revenues against domestic US fee schedule cuts or localized product recalls.
Divestiture as a Portfolio Tool: The 2025 pivot from a planned spinoff to a $2.03 billion sale of Acute Care, Interventional Urology, and OEM lets Teleflex shed the anesthesia/airway, urology, and contract-manufacturing lines and refocus on Arrow vascular access, interventional, and surgical franchises.

Frequently Asked Questions (FAQs)

How many FDA 510(k)s and PMAs does Teleflex hold?

Counted across all of its corporate entities (Arrow/Teleflex, Vascular Solutions, and NeoTract), Teleflex holds roughly 440 active 510(k) clearances — about 300 under the Arrow and Teleflex names, ~123 under Vascular Solutions, and ~17 under NeoTract (UroLift). Its PMA footprint is narrow: 2 distinct PMA devices (MANTA, P180025, and the legacy Vascular Solutions Duett/D-Stat, P990037). Arrow's vascular-access and balloon-catheter lines are 510(k) Class II devices, not PMAs.

Which Teleflex products have been subject to FDA Class I recalls?

Notable recent Class I recalls include Arrow QuickFlash Radial Artery Catheterization Kits (April 2024; 334,995 kits; 10 injuries, 1 death), Arrow FiberOptix and UltraFlex Intra-Aortic Balloon Catheter Kits (June 2024; 16,959 devices; 31 injuries, 3 deaths), Arrow catheters recalled for separation/leakage (June 2023; 250,000+ units; 18 injuries), and Arrow Pressure Injectable Catheter Kits (November 2023; 1,905 kits; mislabeling; no injuries).

How does Teleflex's global registration footprint compare across major markets?

Teleflex holds its largest non-US footprint in Canada (632 MDALL licenses), followed by India (327 CDSCO registrations), South Korea (292 MFDS approvals), Saudi Arabia (272 SFDA authorizations), Australia (267 TGA ARTG listings), and Singapore (138 HSA listings).

What is the 2025 Teleflex transaction and which businesses go where?

Teleflex first announced (February 2025) a plan to spin off Urology, Acute Care, and OEM into a new public company, but on December 9, 2025 it instead agreed to sell those businesses for $2.03 billion: Acute Care and Interventional Urology (including UroLift) to Intersurgical, and OEM to Montagu and Kohlberg. Remaining Teleflex keeps Arrow vascular access, interventional (Vascular Solutions and Biotronik VI), and surgical (Weck, MANTA) franchises. The sales are expected to close in the second half of 2026.

Sources & Regulatory References

Teleflex Investor Relations: Teleflex Q4 & FY2024 Financial Results - Financial revenues, segment reporting, and corporate earnings.
Teleflex Investor Relations: Teleflex Announces Sale of Acute Care, Interventional Urology, and OEM Businesses for $2.03 Billion - December 9, 2025 sale to Intersurgical and Montagu/Kohlberg (superseding the February 2025 spinoff plan).
Teleflex Corporate Announcement: Teleflex Intent to Separate Into Two Companies - The original February 27, 2025 spinoff plan that was later replaced by the sale.
FDA Recall Database: FDA Arrow QuickFlash Class I Recall Notice - April 2024 Class I recall (334,995 kits, 10 injuries, 1 death).
FDA Recall Database: FDA Arrow FiberOptix and UltraFlex IAB Catheter Kits Recall Notice - June 2024 Class I recall (16,959 devices, 31 injuries, 3 deaths).
Health Canada MDALL: Health Canada Medical Devices Active Licence Listing - License search for Teleflex Medical and Arrow International.
Teleflex 2024 Annual Report: Teleflex Annual Report & Proxy Filings - Overview of core brand franchises and global operational sites.